We've updated our Privacy Policy to make it clearer how we use your personal data. We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement

David de Graaf Appointed as a Scientific Advisory Board Member for Swiss Institute of Bioinformatics

Listen with
Speechify
0:00
Register for free to listen to this article
Thank you. Listen to this article using the player above.

Want to listen to this article for FREE?

Complete the form below to unlock access to ALL audio articles.

Read time: Less than a minute

“We are very happy to have David as a member of the SIB Scientific Advisory Board,” said Ron Appel, Ph.D., Executive Director at SIB and Professor of Bioinformatics at the University of Geneva. “David’s thoughtful insights, drawn from his extensive experience in systems biology, will be instrumental in helping to drive the development of SIB’s many bioinformatics resources. He is one of the pioneering minds of systems biology and we are looking forward to a fruitful and brilliant cooperation.”

The SIB is an academic, non-profit foundation established in 1998 to coordinate research and education in bioinformatics throughout Switzerland. The SIB’s mission is to provide world-class core bioinformatics resources to the global research community in key fields such as genomics, proteomics and systems biology, such as UniProtKB/Swiss-Prot, SWISS-MODEL or STRING. Dr. de Graaf was appointed on July 1 by the SIB Foundation Council at its annual meeting, together with Professor Alexey I. Nesvizhskii from the University of Michigan in Ann Arbor. They join Professors Manolo Gouy (Chairman), Christine Orengo, Ron Shamir, Anna Tramontano and Alfonso Valencia, five distinguished experts who have been serving on the Scientific Advisory Board for several years.

“I feel privileged to be elected as a Scientific Advisory Board member at SIB,” said David de Graaf, Ph.D., President and CEO of Selventa. “Effective interpretation of siloed large-scale data is a key initial step in translating critical biological information into clinical applications. I am excited to engage SIB’s distinguished advisors and participate in recommending future initiatives that impact life sciences institutions globally.”